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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: End-stage renal disease (ESRD) may increase the likelihood of malig-
nancy. The aim of this study is to evaluate the characteristics of increased urothelial cancer
(UC) risk in patients with ESRD in Taiwan by a population-based study.
Methods: The standardized incidence ratios (SIRs) for UC among a registered cohort of ESRD in
Taiwan during 1997e2002 were calculated using reimbursement data obtained from the Bu-
reau of National Health Insurance (NHI), with the incidence rates of UC in the general popula-
tion as the reference.
Results: During the study period we identified 58,739 patients with ESRD, 20,939 patients with
UC, and 1305 patients with ERSD and UC. Among the 1305 patients with both diseases, 687
developed UC after ESRD had been diagnosed. Using the general population as the reference
group, SIRs were 12.9 [95% confidence interval (CI)]: 12.0e13.9) for all UC cases, 13.9 (95%
CI: 12.4e15.0) for bladder cancer, 11.9 (95% CI: 8.6e16.0) for renal cell carcinoma, and
11.6 (95% CI: 10.1e13.1) for upper tract urothelial cancer.
Conclusion: Patients with ESRD are at increased risk for UC in Taiwan, especially women age 50
years and younger. Early and lifelong surveillance of UC is recommended after diagnosis of ESRD.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.rsity Road, Tainan 701, Taiwan.
com (J.-D. Wang).
ight ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
3.10.022
SIR of urinary tract cancer in ESRD 53Introduction
Various studies carried out in different regions around the
world have found that the incidence of malignancy is
generally higher in patients suffering from end-stage renal
disease (ESRD),1e4 and renal cell carcinoma (RCC) is espe-
cially high in renal cancer after exclusion of cases related
to analgesic nephropathy.2 In Taiwan, several studies have
revealed that the incidence rate for urothelial cancer (UC),
especially transitional cell carcinoma (TCC), among pa-
tients undergoing renal replacement therapy ranges from
0.89% to 1.69%, but RCC is even lower.5e8
In our previous study the accumulated incidence rate for
UC in the general population using a 200,000 randomized
person dataset from the National Health Insurance (NHI) was
approximately 0.12%, whereas in patients with ESRD it was
much higher (2.1%). Because patients with either major
cancer or ESRD in Taiwan can be registered in the “Cata-
strophic Illness” category, making them exempt from
copayments, there is a strong financial incentive for the
comprehensive inclusion of such cases. The registry gener-
ally requires valid documentation to prevent any potential
abuse, thereby preserving the financial system of the NHI.
Thus, with this valuable reimbursement database we can
initiate a nationwide study to determine whether there is
any discernible increase in UC, especially those in the upper
tract, in patients with ESRD. The aim of this study is to
evaluate the characteristics of UC incidence in this specific
population and to select the patients who are at higher risk.
Methods
The NHI scheme was established in Taiwan in March 1995.
The National Health Research Institute (NHRI) transforms
NHI reimbursement data into files for research. These files
have proved invaluable in providing detailed information on
the healthcare services used by each patient, including
outpatient visits, hospitalizations, and prescriptions. Data
collection began in 1996 and by January 1997, the database
had already become extremely comprehensive. The records
show that the system covered approximately 96% of the
total population in Taiwan during 1997e2002.9 For each
outpatient visit, the data contain up to three diagnoses
(coded under the International Classification of Diseases,
ICD-9), comprising all prescription drugs and dosages (both
conventional medicines and Chinese herbal products), any
special treatment obtained (including dialysis and kidney
transplantation), and the dates of such orders. For hospi-
talization, up to five diagnoses are recorded. To protect the
privacy of all persons registered in the scheme, the iden-
tification numbers of all persons contained within the NHI
database are encrypted and converted into research files
by the NHRI.
Study population
The files in the “Registry of Catastrophic Illness” were ob-
tained for the years 1997e2002; these files include basic
records on all patients with catastrophic illnesses, including
ESRD, kidney transplants, and UC. A histopathology report
is required as a validation document.Files on patients with diagnoses of ESRD and UC made
during the period 1997e2002 were obtained from the reg-
istry. UC was identified as bladder cancer (ICD-9 code 188),
upper tract urothelial cancer (UT-UC; ICD-9 codes 189.1
and 189.2), and RCC (ICD-9 code 189.0). Cases with ICD-9
code 189.9 were excluded because they did not contain
detailed pathological data. Data on patient demographics
(sex, date of birth), diagnoses and treatment (the date
treatment began and the date of death or transplantation),
and duration of renal replacement therapy prior to diag-
nosis of UC were obtained from the databases and used to
calculate the incidence rates of the different types of
urinary cancer.
The reference group included all people enrolled in the
NHI, or the general population of Taiwan. Thus, patients
with UC categorized as ICD-9 codes 188, 189.0, 189.1, and
189.2 were taken as the numerators for the reference
population or ESRD patient cohorts. The entire procedure
for the selection of the patients is illustrated in the flow-
chart in Fig. 1.
This study was approved by the Ethics Review Board of
the National Taiwan University Hospital, Taipei, Taiwan. In
addition, the study complied with personal data protection
regulations.
Statistical analysis
The total number of new cases and the incidence rates of
UC among patients with ESRD and the reference (general)
population were calculated as the number of new patients
with UC per 100,000 person-years at risk. The age-stratified
incidence rates for UC in the reference population were
used to calculate the number of expected cases under the
assumption that the reference population had the same
cancer experience as patients with ESRD for each age
strata. The total number of observed UC cases summed up
across all age strata divided by the total number of ex-
pected cases was then defined as the standardized inci-
dence ratio (SIR). We then calculated the 95% confidence
intervals (95% CIs) under the assumption of Poisson distri-
bution. Potential risk factors, including age and sex, were
assessed for any independent association with new occur-
rences of UTC, concluding with the calculation of age- and
sex-stratified incidence rates. All of the above analyses
were carried out using the SAS software package, version
8.2 (SAS Institute Inc. Cary, NC, USA).
Results
There were approximately 22 million people registered
with the NHI system between the years 1997 and 2002 (as
summarized in Fig. 1). Patients with missing information
were excluded. During the 6-year cross-sectional study
(1997e2002) of the 22 million individuals in the reference
group without ESRD, 20,171 developed UC. Among them,
6,816 (34%) were women and 13,355 (66%) were men. The
mean age was 65.6  13.9 years. In the reference popula-
tion, 7% had renal cancer, 34% had renal pelvic and ureteral
cancers, and 59% had bladder cancer. Among patients with
ESRD, 6% had renal cancer, 30% had renal pelvic and ure-
teral cancers, and 64% had bladder cancer.
Figure 1 Flowchart of recruitment of cases.
Figure 2 Incidence rates of urinary tract cancer in patients
with ESRD (end stage renal disease) and general population of
Taiwan.
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However, 618 individuals who developed ESRD after the
diagnosis of UC were excluded from the numerators. One
patient with incomplete data was also excluded. Thus, a
total of 58,120 patients with ESRD were at risk of developing
UC during the follow-up period, and in 687 of them UC had
developed at the 6-year follow-up. Among patients with
ESRDwithout UC, 52.3% were women (nZ 30,027) and 47.3%
were men (nZ 27,406). Among the 687 patients in whom UC
developed, 62% were women (n Z 426) and 38% were men
(nZ 261). The odds ratio of men and women to develop UTC
was statistically significant (p< 0.0001). Themean age of the
patients was 60.8  11.1 years. UC comprised RCC in 41 pa-
tients, bladder cancer in 436 patients, and UT-UC in 210
patients. Among the patients with ESRD, 1834 underwent
kidney transplantation and UC developed in 28 of them after
transplantation. Only three of the 365 patients with ESRD
who later developed UC resided in arsenic-endemic areas,
namely, the townships of Peimen, Hsuechia, Putai, and Ichu
in southwestern Taiwan.10,11 The odds ratio of developing
UTC did not differ significantly between patients living in
arsenic-endemic areas and patients living in nonarsenic-
endemic areas (pZ 0.51).
The incidence rates of UC among patients with ESRD and
the reference population, after stratification by age, areillustrated in Fig. 2. The SIRs for all types of UC were much
higher among the patients with ESRDs than among those in
the reference population across all age groups. As sum-
marized in Table 1, the SIRs for the ESRD cohort were 12.9
(95% CI: 12.0e13.9) for all UC cases, 13.9 (95% CI:
12.4e15.0) for bladder cancer, 11.9 (95% CI: 8.6e16.0) for
renal cancer, and 11.6 (95% CI: 10.1e13.1) for renal pelvic
and ureteric cancers. Discernibly higher SIRs were noted
SIR of urinary tract cancer in ESRD 55among women and patients with age below 50e60 than
those above that age, especially for bladder cancer. We
also found that the SIRs for the different types of UC
declined among patients older than 70 years, with the rate
coming close to 1 (Fig. 2).
The average duration between the diagnosis of UC and
the diagnosis of ESRD was 2.17 years (0.003e5.9 years). The
average duration was 2.4 years for patients with RCC, 2.3
years for patients with bladder cancer, and 1.8 years for
patients with UT-UC. In addition, UC developed earlier in
the upper tract than in the bladder and developed earlier
than RCC after renal replacement therapy.Discussion
This study indicates, for the first time, that patients with
ESRD in Taiwan are at increased risk for developing UC, with
women and those below 50e60 years old at a particularly
high risk. Further inference is necessary to evaluate
possible etiologies.
Prior to making further inference, however, we must
examine all potential confounding factors. First, we need
to rule out the possibility of overdiagnosis. In order for
patients with UC to be registered under the “catastrophic
illness” category, every patient is required to submit a
histopathology report as a validation document, although a
very minor proportion (<5e10%) of patients with inoper-
able cancer is allowed to submit a cytology report plus
evidence of imaging in lieu of submitting a pathology
report. The data obtained from the National Cancer Reg-
istry of Taiwan showed that 90e95% of the diagnoses of UC
were verified by histopathologic proof. Moreover, the
annual incidence rates calculated from the cancer registry
for UT-UC and bladder cancer were 3.5 cases per 100,000Table 1 Distribution of cancers of the urinary tract, bladder, kid
in Taiwan.*
Sample All urinary tract cancer Bladder urothelial cance
Obs. Exp. SIR (95% CI) Obs. Exp. SIR (95% CI)
Male 261 32.7 7.9 (7.1, 9.0) 166 21.5 7.7 (6.6, 9.0)
Female 426 19.3 22.1 (20.1, 24.3) 270 8.9 29.6 (26.3, 33.3
Total 687 53.1 12.9 (12.0, 13.9) 436 31.4 13.7 (12.4, 15.0
Male
<40 13 0.3 46.7 (1.7, 27.1) 3 0.1 24.7 (8.0, 76.6)
40e49 38 3.3 11.5 (8.4, 15.9) 24 2.0 12.3 (8.3, 18.4)
50e59 62 12.4 5.0 (3.9, 6.4) 34 7.4 4.6 (3.3, 6.4)
60e69 86 37.8 2.3 (1.8, 2.8) 55 24.1 2.3 (1.8, 3.0)
>70 62 58.4 1.1 (0.8, 1.4) 50 42.8 1.2 (0.9, 1.5)
Female
<40 11 0.2 74.5 (1.8, 41.2) 8 0.04 205.4 (102.7, 41
40e49 59 2.0 29.9 (23.2, 38.6) 36 0.8 46.0 (33.2, 63.7
50e59 122 7.0 17.4 (14.6, 20.1) 79 3.1 25.4 (20.3, 31.6
60e69 149 26.6 5.6 (4.8, 6.6) 98 12.1 8.1 (6.6, 9.8)
>70 85 36.2 2.4 (1.9, 2.9) 49 18.4 2.7 (2.0, 3.5)
Note: *The table provides details of the total number of observation
incidence ratio (SIR) and the 95 per cent confidence interval (95 perpersons and 7.1 cases per 100,000 persons, respectively, in
the year 2001, rates that are close to the rates of 3.6 and
6.23, respectively, calculated from the catastrophic regis-
try. Thus, the potential bias of overdiagnosis cannot explain
our finding. Second, the possibility of diagnosis bias must be
considered. In general, patients with ESRD often experi-
ence hematuria prior to when the diagnosis of UC is made.12
In Taiwan, the convenience of our NHI system makes the
accessibility to healthcare services relatively easy and
equal.13 Although cancer is definitively diagnosed, patients
can be registered under the catastrophic illness category,
making them eligible for a copayment waiver. Thus, every
patient with cancer and persistent hematuria will ulti-
mately be detected, thereby minimizing the likelihood of
an erroneous diagnosis. Therefore, we tentatively conclude
that the increased SIR of UC in patients with ESRD is real
and deserves further exploration into the possible etiolog-
ical mechanism.
In general, relatively little is known about the patho-
physiological mechanisms of and risk factors for UC and
renal cancer. Indeed, UC among patients with ESRD and
among those who undergo kidney transplantation only
recently attracted the attention of clinicians, when spo-
radic case reports of UC began to be seen in the early
1990s; since then, there has been a rapid increase in such
reports in Taiwan.8,14e16 Studies from Western countries
indicate that the incidence of pelvic tumor among all uri-
nary cancer is 5%,17 and ureteral tumors are even less, or,
about a quarter in upper tract cancer,18 and the odds ratio
of developing UC among ESRD is generally less than three
times.19e21 In this study we found that proportions of
bladder cancer, UT-UC, and RCC among ESRD were 59%, 34%
and 7%, respectively, which are similar to those of general
population of 64%, 30% and 6%, respectively. In addition to
high proportions of UT-UC in renal cancer among theney, ureter and pelvis in patients with end-stage renal disease
r Ureter and pelvic urothelial
cancers
Renal cell carcinoma
Obs. Exp. SIR (95%CI) Obs. Exp. SIR (95% CI)
75 9.2 8.1 (6.5, 10.2) 19 1.8 10.5 (6.7, 16.5)
) 134 8.9 15.2 (12.7, 17.9) 22 1.7 13.4 (8.8, 20.3)
) 209 18.2 11.5 (10.1, 13.1) 41 3.5 11.7 (8.6, 16.0)
8 0.1 65.3 (32.7, 130.7) 1 0.03 31.8 (4.5, 225.4)
11 1.1 10.1 (5.6, 18.2) 3 0.2 12.6 (4.1, 38.9)
20 4.0 5.0 (3.2, 7.7) 8 1.0 8.5 (4.2, 16.9)
26 11.4 2.3 (1.6, 3.4) 5 2.2 2.3 (0.9, 5.5)
10 13.5 0.7 (0.4, 1.4) 2 2.2 0.9 (0.2, 3.6)
0.8) 3 0.1 35.5 (11.1, 107.1) 0 0.02
) 22 1.0 22.7 (14.9, 34.5) 1 0.2 4.6 (0.6, 32.9)
) 34 3.2 10.7 (7.6, 14.9) 9 0.7 13.9 (7.2, 26.7)
41 12.1 3.4 (2.5, 4.6) 10 2.2 4.6 (2.5, 8.6)
34 15.1 2.3 (1.6, 3.2) 2 2.5 0.8 (0.2, 3.2)
s (Obs), the expected number of cases (Exp,) the standardized
cent CI).
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world’s highest incidence and second highest prevalence of
ESRD.22 Thus, we attempted to determine possible patho-
gens for these phenomena, albeit they might share the
same mechanism. Most strikingly, our results showed that
women with ESRD and patients younger than 50 years are at
increased risk for developing UC. Because few women in
Taiwan are engaged in occupations that would expose them
to carcinogens and based on the fact that the prevalence of
cigarette smoking has consistently been lower than 5%
during the past four decades, it is unlikely that occupa-
tional exposure to carcinogens or smoking is responsible for
the increased incidence of UC among women. Genetic
alternation in upper urinary tract urothelial carcinoma with
more copy number variants is noted in patients with
ESRD.23 Arsenic exposure has been associated with an
increased incidence of kidney and bladder cancer in Taiwan
since 1920.11,24e26 Chen et al27 reported their findings that
more than 20% female patients with nonmuscle-invasive
bladder UC had synchronous ESRD and required perma-
nent dialysis. However, bilateral nephroureterectomy from
renal or ureteral UC is not the major reason to dialysis.
There is limited evidence to address the association of ESRD
and bladder cancer in Western countries. In Taiwan,
another group identified the unusual association between
chronic dialysis and the development of UC in Taiwan.6
They also reported that the SIR of UC for patients
receiving chronic dialysis was 48.2 compared with that of
the general population. It is remarkably higher in women
(65.1) than in men (38.1).6 However, the mechanism to
explain the strong association among female predomi-
nance, chronic dialysis, and UC remained elusive. In this
study, the incidence of UC in arsenic-endemic areas
(including four townships with blackfoot disease) was high.
During the 6-year study period we found that the SIRs were
3.2 (n Z 19) for RCC, 55.5 (n Z 333) for bladder cancer,
and 26.1 (n Z 157) for UT-UC. A total of 355 patients with
ESRD lived in those endemic areas; however, only three
developed UC. The exclusion of those three patients did not
change the summary results, indicating that the develop-
ment of UC is not associated with arsenic exposure.
In a recent population-based caseecontrol study in
Taiwan, we found that UC was associated with cumulative
prescriptions of aristolochic acid (AA)-related Chinese
herbal products even after limiting the analysis to those
who consumed fewer than 500 pills of nonsteroidal anti-
inflammatory drugs or acetaminophen.28 The study appears
to corroborate the findings reported in studies from
Belgium and the Balkan states.29e32 Given that more than
25% of all Taiwanese citizens are known to regularly
consume Chinese herbal products containing AA, a chemical
that is associated with the development of CKD,33 ESRD,34
and UC,28 it seems logical to assume that the increased
risk for the development of UC in patients with ESRD in
Taiwan might be related to the consumption of AA-
associated herbal products.32e34 Racial and etiologic dif-
ferences might partially explain the different ratios in RCC
and UC.
The major limitation of this study is its cross-sectional
design and the limitation of the NHI database. Because the
data from that database do not include the history of
smoking or specific exposures to toxic materials precludesus from making detailed analysis or further inference.
Therefore, our conjecture that the increased incidence of
UC might be associated with the consumption of AA-related
herbal products needs more corroborative study and must
be interpreted with caution.
In conclusion, with a national database, we found that
SIRs of UT-UC, bladder cancer, and RCC among dialysis
patients with ERSD are much higher than those that
occurred in the general population of Taiwan. In the diag-
nosis of ESRD, UT-UC comprised 37% of all UC, higher than
30% in the general population, and both much higher than
5% in Western countries. In ESRD patients below 50 years of
age, SIRs of bladder UC and UT-UC are about more than 10
times in males and 30 times in females if compared to
general population. Those of RCC were about 10 times
higher in both genders, which were lower than the reported
SIR 30e40 times in western countries. In exposure, we hy-
pothesized that Chinese herbal products might play an
important role in the development of UTC in patients with
ESRD. We recommend that clinicians who care for patients
with ESRD in countries where Chinese herbal products are
commonly used conduct similar studies to corroborate the
aforementioned hypothesis. In addition, special attention
may be paid to any sign of UC, such as hematuria and
hydronephrosis, for early detection of disease.Acknowledgments
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